pyrazinoic acid has been researched along with Koch's Disease in 19 studies
pyrazinoic acid: active metabolite of pyrazinamide; structure
pyrazine-2-carboxylic acid : The parent compound of the class of pyrazinecarboxylic acids, that is pyrazine bearing a single carboxy substituent. The active metabolite of the antitubercular drug pyrazinamide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pyrazinamide has been a mainstay in the multidrug regimens used to treat tuberculosis." | 7.96 | The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD. ( Li, X; Perez, LM; Sacchettini, JC; Shi, W; Sun, Q; Zhang, Y, 2020) |
| "Pyrazinamide (PZA) is an important component of first-line drugs because of its distinctive capability to kill subpopulations of persistent Mycobacterium tuberculosis (MTB)." | 7.91 | Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan. ( Afzal, MT; Ali, S; Khan, AS; Khan, MT; Malik, SI; Masood, N; Nadeem, T, 2019) |
| "Through mutant selection on agar containing pyrazinoic acid (POA), the bioactive form of the prodrug pyrazinamide (PZA), we recently showed that missense mutations in the aspartate decarboxylase PanD and the unfoldase ClpC1, and loss-of-function mutation of polyketide synthases Mas and PpsA-E involved in phthiocerol dimycocerosate synthesis, cause resistance to POA and PZA in Mycobacterium tuberculosis." | 7.85 | In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1. ( Dartois, V; Dick, T; Gopal, P; Lanoix, JP; Li, L; Nuermberger, E; Rasic, G; Sarathy, J; Tasneen, R; Yee, M, 2017) |
| "Pyrazinamide (PZA) is an important front-line anti-tuberculosis drug that is active only at acid pH." | 7.71 | Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. ( Permar, S; Sun, Z; Zhang, Y, 2002) |
| "Pyrazinamide (PZA) is a prodrug requiring conversion to pyrazinoic acid (POA) by an amidase encoded by pncA for in vitro activity." | 5.43 | High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis. ( Alland, D; Dartois, V; Lanoix, JP; Nuermberger, E; O'Brien, P; Pinn, M; Safi, H; Sarathy, J; Tasneen, R, 2016) |
| "46 μm, as measured by inertial impaction, for POA-leu and POA-NH4, respectively) and with properties (stoichiometric 1:1 ratio of salt to drug, melting points at ∼180 °C, with water content of <1%) that would support further development as an inhaled dosage form." | 5.42 | Spray Dried Aerosol Particles of Pyrazinoic Acid Salts for Tuberculosis Therapy. [Corrected]. ( Dhillon, J; Durham, PG; Fourie, PB; German, N; Hickey, AJ; Mitchison, DA; Mortensen, N; Zhang, Y, 2015) |
| "Pyrazinamide has been a mainstay in the multidrug regimens used to treat tuberculosis." | 3.96 | The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD. ( Li, X; Perez, LM; Sacchettini, JC; Shi, W; Sun, Q; Zhang, Y, 2020) |
| "Pyrazinamide is a sterilizing first-line tuberculosis drug." | 3.96 | Pyrazinamide triggers degradation of its target aspartate decarboxylase. ( Akopian, T; Bhushan, S; Dick, T; Gengenbacher, M; Gopal, P; Grüber, G; Kandror, O; Lim, TK; Lin, Q; Ragunathan, P; Rubin, EJ; Sarathy, JP; Shin, J; Yee, M; Zhu, J, 2020) |
| "Pyrazinamide (PZA) is an important component of first-line drugs because of its distinctive capability to kill subpopulations of persistent Mycobacterium tuberculosis (MTB)." | 3.91 | Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan. ( Afzal, MT; Ali, S; Khan, AS; Khan, MT; Malik, SI; Masood, N; Nadeem, T, 2019) |
| "Through mutant selection on agar containing pyrazinoic acid (POA), the bioactive form of the prodrug pyrazinamide (PZA), we recently showed that missense mutations in the aspartate decarboxylase PanD and the unfoldase ClpC1, and loss-of-function mutation of polyketide synthases Mas and PpsA-E involved in phthiocerol dimycocerosate synthesis, cause resistance to POA and PZA in Mycobacterium tuberculosis." | 3.85 | In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1. ( Dartois, V; Dick, T; Gopal, P; Lanoix, JP; Li, L; Nuermberger, E; Rasic, G; Sarathy, J; Tasneen, R; Yee, M, 2017) |
| "The activity of different analogs of pyrazinamide on Mycobacterium tuberculosis fatty acid synthase type I (FASI) in replicating bacilli was studied." | 3.74 | Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli. ( Arai, M; Jacobs, WR; Vilchèze, C; Welch, JT; Zimhony, O, 2007) |
| "Pyrazinamide (PZA) is an important front-line anti-tuberculosis drug that is active only at acid pH." | 3.71 | Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. ( Permar, S; Sun, Z; Zhang, Y, 2002) |
| "Substituted pyrazinoic acid esters have previously been reported to have in vitro activity against Mycobacterium avium and Mycobacterium kansasii as well as Mycobacterium tuberculosis." | 3.69 | Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters. ( Bergmann, KE; Cynamon, MH; Welch, JT, 1996) |
| "Pyrazinamide (PZA) is a critical component of the first-line TB treatment regimen because of its sterilizing activity against non-replicating Mycobacterium tuberculosis (Mtb), but its mechanism of action has remained enigmatic." | 1.72 | Structure activity relationship of pyrazinoic acid analogs as potential antimycobacterial agents. ( Aldrich, CC; Aragaw, WW; Cole, MS; Dick, T; Grüber, G; Harikishore, A; Hegde, PV; Jachak, G; Ragunathan, P; Sharma, S, 2022) |
| "Pyrazinoic acid (1: ) was esterified first (2: ) followed by amination to produce hydrazide (3: ) which was refluxed with POCl3 to obtain 2-chloromethyl-5pyrazino-1, 3, 4-oxadiazole (4: )." | 1.62 | Evaluation and Docking Study of Pyrazine Containing 1, 3, 4-Oxadiazoles Clubbed with Substituted Azetidin-2-one: A New Class of Potential Antimicrobial and Antitubercular. ( Das, R; Mehta, DK, 2021) |
| "Pyrazinamide (PZA) is a prodrug requiring conversion to pyrazinoic acid (POA) by an amidase encoded by pncA for in vitro activity." | 1.43 | High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis. ( Alland, D; Dartois, V; Lanoix, JP; Nuermberger, E; O'Brien, P; Pinn, M; Safi, H; Sarathy, J; Tasneen, R, 2016) |
| "46 μm, as measured by inertial impaction, for POA-leu and POA-NH4, respectively) and with properties (stoichiometric 1:1 ratio of salt to drug, melting points at ∼180 °C, with water content of <1%) that would support further development as an inhaled dosage form." | 1.42 | Spray Dried Aerosol Particles of Pyrazinoic Acid Salts for Tuberculosis Therapy. [Corrected]. ( Dhillon, J; Durham, PG; Fourie, PB; German, N; Hickey, AJ; Mitchison, DA; Mortensen, N; Zhang, Y, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (21.05) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 2 (10.53) | 29.6817 |
| 2010's | 6 (31.58) | 24.3611 |
| 2020's | 5 (26.32) | 2.80 |
| Authors | Studies |
|---|---|
| Zimhony, O | 1 |
| Vilchèze, C | 1 |
| Arai, M | 1 |
| Welch, JT | 3 |
| Jacobs, WR | 1 |
| Hegde, PV | 1 |
| Aragaw, WW | 1 |
| Cole, MS | 2 |
| Jachak, G | 1 |
| Ragunathan, P | 2 |
| Sharma, S | 2 |
| Harikishore, A | 1 |
| Grüber, G | 2 |
| Dick, T | 3 |
| Aldrich, CC | 2 |
| Howe, MD | 1 |
| Buonomo, JA | 1 |
| Lamont, EA | 1 |
| Brody, SI | 1 |
| Mishra, NK | 1 |
| Minato, Y | 1 |
| Thiede, JM | 1 |
| Baughn, AD | 1 |
| Sun, Q | 1 |
| Li, X | 1 |
| Perez, LM | 1 |
| Shi, W | 1 |
| Zhang, Y | 3 |
| Sacchettini, JC | 1 |
| Gopal, P | 2 |
| Sarathy, JP | 1 |
| Yee, M | 2 |
| Shin, J | 1 |
| Bhushan, S | 1 |
| Zhu, J | 1 |
| Akopian, T | 1 |
| Kandror, O | 1 |
| Lim, TK | 1 |
| Gengenbacher, M | 1 |
| Lin, Q | 1 |
| Rubin, EJ | 1 |
| Das, R | 1 |
| Mehta, DK | 1 |
| Khan, MT | 1 |
| Malik, SI | 1 |
| Ali, S | 1 |
| Masood, N | 1 |
| Nadeem, T | 1 |
| Khan, AS | 1 |
| Afzal, MT | 1 |
| Durham, PG | 2 |
| German, N | 1 |
| Mortensen, N | 1 |
| Dhillon, J | 1 |
| Mitchison, DA | 2 |
| Fourie, PB | 1 |
| Hickey, AJ | 2 |
| Corrêa, MF | 1 |
| Fernandes, JP | 1 |
| Lanoix, JP | 2 |
| Tasneen, R | 2 |
| O'Brien, P | 1 |
| Sarathy, J | 2 |
| Safi, H | 1 |
| Pinn, M | 1 |
| Alland, D | 1 |
| Dartois, V | 2 |
| Nuermberger, E | 2 |
| Young, EF | 1 |
| Perkowski, E | 1 |
| Malik, S | 1 |
| Hayden, JD | 1 |
| Zhong, L | 1 |
| Braunstein, MS | 1 |
| Rasic, G | 1 |
| Li, L | 1 |
| FERRARI, S | 2 |
| MORELLINI, M | 2 |
| BONATI, F | 1 |
| BERTONI, L | 1 |
| CASALONE, G | 1 |
| GANZETTI, G | 1 |
| MANGIAROTTI, S | 1 |
| SOLOTOROVSKY, M | 1 |
| GREGORY, FJ | 1 |
| IRONSON, EJ | 1 |
| BUGIE, EJ | 1 |
| O'NEILL, RC | 1 |
| PFISTER, R | 1 |
| Bergmann, KE | 1 |
| Cynamon, MH | 1 |
| Permar, S | 1 |
| Sun, Z | 1 |
1 review available for pyrazinoic acid and Koch's Disease
| Article | Year |
|---|---|
Pyrazinamide and Pyrazinoic Acid Derivatives Directed to Mycobacterial Enzymes Against Tuberculosis.
Topics: Animals; Anti-Bacterial Agents; Humans; Mycobacterium tuberculosis; Prodrugs; Pyrazinamide; Tubercul | 2016 |
18 other studies available for pyrazinoic acid and Koch's Disease
| Article | Year |
|---|---|
Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.
Topics: Bacterial Proteins; Fatty Acid Synthases; Microbial Sensitivity Tests; Mycobacterium tuberculosis; P | 2007 |
Structure activity relationship of pyrazinoic acid analogs as potential antimycobacterial agents.
Topics: Amidohydrolases; Antitubercular Agents; Carboxylic Acids; Drug Resistance, Bacterial; Humans; Microb | 2022 |
Cephem-Pyrazinoic Acid Conjugates: Circumventing Resistance in Mycobacterium tuberculosis.
Topics: Antitubercular Agents; beta-Lactams; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis | 2022 |
The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD.
Topics: Amidohydrolases; Antitubercular Agents; Bacterial Proteins; Carboxy-Lyases; Crystallography, X-Ray; | 2020 |
Pyrazinamide triggers degradation of its target aspartate decarboxylase.
Topics: Antitubercular Agents; Bacterial Proteins; Carboxy-Lyases; Drug Resistance, Bacterial; Endopeptidase | 2020 |
Evaluation and Docking Study of Pyrazine Containing 1, 3, 4-Oxadiazoles Clubbed with Substituted Azetidin-2-one: A New Class of Potential Antimicrobial and Antitubercular.
Topics: Antifungal Agents; Antitubercular Agents; Aspergillus niger; Azetidines; Candida albicans; Drug Eval | 2021 |
Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan.
Topics: Adolescent; Adult; Aged; Amidohydrolases; Antitubercular Agents; Child; Drug Resistance, Bacterial; | 2019 |
Spray Dried Aerosol Particles of Pyrazinoic Acid Salts for Tuberculosis Therapy. [Corrected].
Topics: Administration, Inhalation; Antitubercular Agents; Desiccation; Dry Powder Inhalers; Humans; Nanopar | 2015 |
High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis.
Topics: Animals; Antitubercular Agents; Female; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Myco | 2016 |
Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.
Topics: Administration, Inhalation; Aerosols; Animals; Antitubercular Agents; Esters; Guinea Pigs; Male; Mic | 2016 |
In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Carboxy-Lyases; Culture Media; Disease Models, A | 2017 |
[Activity of pyrazinamide (pyrazine-2-carboxylic acid amide) in experimental tuberculosis of the cavy].
Topics: Amides; Guinea Pigs; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1956 |
[Activity of pyrazinamide (pyrazine-2-carboxylic acid amide) in experimental tuberculosis of the cavy].
Topics: Amides; Guinea Pigs; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1956 |
[Activity of pyrazinamide (pyrazine-2-carboxylic acid amide) in experimental tuberculosis of the cavy].
Topics: Amides; Guinea Pigs; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1956 |
[Activity of pyrazinamide (pyrazine-2-carboxylic acid amide) in experimental tuberculosis of the cavy].
Topics: Amides; Guinea Pigs; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1956 |
[Basic derivatives of pyrazine-2-carboxylic acid with antimycobacterial action. Microbiological and pharmacological study].
Topics: Anti-Bacterial Agents; Humans; Pyrazinamide; Tuberculosis | 1962 |
[Experimental and clinical research on the antitubercular activity of the N-(4-morpholinomethyl)-amide of pyrazinecarboxylic acid].
Topics: Amides; Antitubercular Agents; Humans; Pyrazinamide; Tuberculosis | 1962 |
Pyrazinoic acid amide; an agent active against experimental murine tuberculosis.
Topics: Amides; Animals; Humans; Mice; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1952 |
Pyrazinamide--on the antituberculosis drug frontline.
Topics: Amidohydrolases; Animals; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Resistance, | 1996 |
Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Esters; Humans; Microbial Sensitivity | 1996 |
Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.
Topics: Antitubercular Agents; Cell Survival; Colony Count, Microbial; Culture Media; Drug Interactions; Dru | 2002 |